Xbrane Biopharma (Q4 initial take): Below expectations - Redeye

Xbrane's year-end report showed lower revenue, consisting almost exclusively of delieveries to STADA leading to a higher loss on the EBIT level than we had projected. Redeye will downwards revise estimates and foresee an adverse reaction in the stock once the market opens.

Länk till analysen i sin helhet: https://www.redeye.se/research/1152946/xbrane-biopharma-q4-initial-take-below-expectations?utm_source=finwire&utm_medium=RSS